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Abstract 
Hepatitis B is an infectious disease caused by the Hepatitis B Virus (HBV) with a risk of transplacental (mother-
to-child) transmission which is responsible for the failure of child’s hepatitis B vaccination especially in mother 
with positive HBeAg serum. HBeAg plays a role in transplacental transmission by inducing in utero 
immunological tolerance by increasing the Regulatory T cells. This study aims to determine the expression of 
FOXP3 in the placenta as Regulatory T cells marker with positive and negative maternal HBeAg serum. This 
study was conducted in a cross-sectional study using 66 placental samples of mothers with positive HBsAg 
serum, group in positive and negative maternal HBeAg serum, also in positive HBV DNA serum with positive 
HBV DNA cord blood and positive HBV DNA serum with negative HBV DNA cord blood. FOXP3 expression 
was positive in 21 samples (31.8%), stained brown in Regulatory T cells. It was concluded that there was no 
significant difference between placental FOXP3 expression with maternal HBeAg serum and intrauterine 
transmission status (chi-square test, p = 0.575 and p = 1,000  (p > 0.05)). 
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1. Introduction 
Hepatitis B Virus (HBV) infection is a world health problem that has a significant effect on socioeconomic 
condition [1,2]. More than 240 million of the world's population are infected with HBV and 40% among them 
are progressively developed into chronic hepatitis or/and hepatocellular carcinoma [3]. This risk is related to age 
at the time of infection. 90% of individuals who get perinatal HBV infection will develop chronic hepatitis. East 
Asia, Central Asia, Sub-Saharan, and the Pacific Region have a high prevalence of HBV infection during infant 
or young age (5-8%) [4-7]. In Asian countries, most HBV infection goes through vertical transmission from 
mother to child. The prevalence of chronic HBV infection in pregnant women with the risk of vertical 
transmission (Mother to Child Transmission) is 0.82% [6]. Mother to Child Transmission (MTCT) is 
responsible for more than one-third of chronic hepatitis B infections worldwide [7]. MTCT occurs more often in 
positive HBeAg serum and in high DNA viral serum level mothers [4]. Giving hepatitis B vaccine and hepatitis 
B immunoglobulin (HBIG) in newborns can prevent transmission during labor and postpartum. However, about 
5-10% of the vertical transmission of HBV cannot be prevented because of the failure of protection against 
intrauterine infection. Unfortunately, there is no standard strategy during the gestational period to prevent this 
intrauterine transmission [8]. In some HBV endemic areas such as West Africa, transplacental transmission of 
the hepatitis B virus is very rare. However, in East Asia where genotypic B is endemic, the transplacental 
transmission is common, especially in seropositive HBeAg mothers [9]. Positive HBeAg serum can induce in 
utero immune tolerance because viral particles can cross the placental barrier. HBV infection obtained from the 
mother, in general, is in the immune tolerance stage until the patient becomes an adult. The exact mechanism of 
vertical transmission remains unclear, presumably, HBV transmission occurs perinatally at birth or in utero 
which results in immune tolerance status in infected infants [6,10]. Some studies suggested HBeAg causes 
chronic infection through in utero tolerance of T cells to HBV. HBeAg from positive HBsAg serum mothers 
inhibits T cells and dendritic cells function in fetal by increasing Regulatory T cells (Tregs) thereby reducing the 
immune response to HBV and increasing the risk of intrauterine transmission [7,11,12]. During HBV infection 
there is an increase in Tregs that cause suppression of T cells effector in immune tolerance patient. Infants born 
from mothers with chronic HBV infection have high circulating Tregs [6]. Forkhead Box Protein 3 (FOXP3) is 
widely used as a definitive marker of Tregs in patients with cancer and autoimmune diseases. FOXP3 is very 
important for the development and function of Tregs in mice and humans. In particular, the expression of 
FOXP3 in Tregs shows different function and phenotype between Tregs and T cells effector [13,14]. Tregs are 
produced through up-regulation of FOXP3 expression so there is a conversion from naive T cells to Tregs. 
FOXP3 inactivation causes Tregs deficiency [15].  The studies of the expression of FOXP3 in the placenta in 
correlation with HBV transmission have never been done before. 
2. Materials and Methods 
2.1.Collections of Samples 
In this study, we obtained 66 placenta samples with positive maternal HBsAg serum from 1056 pregnant women 
during the period of December 2017 to August 2018 conducted in various hospitals in Makassar, Indonesia. 
Samples were then divided into two groups based on the data of maternal HBeAg serum by ELISA examination, 
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and the data of HBV DNA serum and HBV DNA cord blood examination by PCR. There were 11 samples with 
positive HBV DNA serum from 66 samples. These samples were undergone HBV DNA cord blood examination 
to see intrauterine transmission status; positive HBV DNA serum with positive HBV DNA cord blood indicates 
transmission, and positive HBV DNA serum with negative HBV DNA cord blood indicates no transmission. 
2.2. Detection of FOXP3 in placental tissue by Immunohistochemistry 
The placental tissue was processed into a paraffin block. The paraffin block was cut to size 5 µm, mounted to 
the poly-L-lysine object glass and then deparaffinized. Immunohistochemical staining used the standard method 
of Avidin-Biotin-Peroxidase Complex (ABC). Unstained slides were incubated with peroxidase-1 for 5 minutes 
at room temperature and followed with the ABC procedure. Immunohistochemical staining used concentrated 
FOXP3 monoclonal antibody with 1: 50 dilution. The positive control was done in parallel using tonsillar tissue. 
Positive cells were stained brown in Regulatory T cells, observed on a light microscope. Immunohistochemical 
staining results were evaluated by two pathologists. 
2.3. Data Analysis 
Data analysis was using a chi-square test to see the correlation between placental FOXP3 expression and 
maternal HBeAg serum status. 
3. Result  
 
Figure 1: Positive Expression of FOXP3 only in Placental Lymphocytes (400X). 
 
Figure 2: Negative expression of FOXP3 in both Trophoblast and Placental Lymphocytes (400X). 
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Table 1: Samples Distribution 
 
HBeAg Serum FOXP3 Expression 
N % N % 
Negative 50 75,8 45 68,2 
Positive 16 24,2 21 31,8 
Total 66 100 66 100 
Based table 1, from placental samples of mothers with positive HBsAg serum, we obtained positive maternal 
HBeAg serum as many as 16 samples (24.2%) and negative HBeAg serum as many as 50 samples (75.8%), and 
positive FOXP3 expression as many as 21 samples (31.8%) and negative FOXP3 expression as many as 45 
samples (68.2%). 
Table 2: Correlation of  Placental FOXP3 Expression with Maternal HBeAg Serum 
 Negative FOXP3 Positive FOXP3 Total 
Negative HBeAg 35 (70%) 15 (30%) 50 (100%) 
Positive HBeAg 10 (62,5%) 6 (37,5%) 16 (100%) 
Total 45 (68,2%) 21 (31,8%) 66 (100%) 
Chi-square test 
According to table 2, from 50 placenta samples of mother with negative HBeAg serum, there were 15 samples 
with positive FOXP3 expression (30%) and 35 samples with negative FOXP3 expression (70%), and from 16 
placenta samples of mother with positive HBeAg serum, there were 6 samples with positive FOXP3 expression 
(37.5%) and 10 samples with negative FOXP3 expression (62.5%). Based on these, it was concluded that there 
was no correlation between the expression of FOXP3 in placenta with HBeAg serum status of mother (chi-
square test, p = 0.575 (p > 0.05)). 
Table 3: Correlation of  Placental FOXP3 Expression with Intrauterine Transmission Status 
 
Positive HBV DNA Serum and 
Positive HBV DNA Cord Blood 
(Positive Intrauterine 
Transmission) 
Positive HBV DNA Serum and 
Negative HBV DNA Cord Blood 
(Negative Intrauterine 
Transmission) 
Total 
Negative FOXP3 2(100%) 6 (66,7%) 8 (72,7%) 
Positive FOXP3 0 (0%) 3 (33,3%) 3 (27,3%) 
Total 2(100%) 9 (100%) 11 (100%) 
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Chi-square test 
According to table 3, from 66 positive HBsAg mothers, 11 positive HBV DNA serum samples were obtained, 
consisted of 2 samples with positive HBV DNA cord blood and 9 samples with negative HBV DNA cord blood. 
Positive placental FOXP3 expression in positive HBV DNA serum and positive HBV DNA cord blood were 0 
samples (0%) and negative placental FOXP3 expression with positive HBV DNA serum and positive HBV 
DNA cord blood were 2 samples (100%). Positive placental FOXP3 expression in positive HBV DNA serum 
and negative HBV DNA cord blood were 3 samples (66.7%) and negative placental FOXP3 expression with 
positive HBV DNA serum and negative HBV DNA cord blood were 6 samples (66.7%). Based on these data, it 
was concluded that there was also no correlation between expression of FOXP3 in placenta with intrauterine 
transmission status of mother (chi-square test, p = 1,000 (p> 0.05)). 
4. Discussion  
Hepatitis B is a global health problem and is the cause of chronic hepatitis, cirrhosis and liver cell carcinoma. 
According to WHO, hepatitis B is the second carcinogen in humans after tobacco cigarettes. The Hepatitis B 
virus can integrate with the placenta and cause infection. In the study of pregnant women with positive HBeAg 
serum, HBeAg can cross the placenta barrier. Positive HBsAg and HBeAg serum mothers tend to transmit to 
their children (70-90%) compared to positive HBsAg and negative HBeAg serum mothers [16]. In this study, 
we took placental samples from positive HBeAg-positive HBsAg serum and negative HBeAg-positive HBsAg 
serum mothers.  Total positive HBsAg serum samples were 66 samples. From table 1, the number of positive 
HBeAg serum samples is 16 samples or 24.2% of the total sample. In a study of Wu and his colleagues in 
Taiwan, positive HBeAg serum from positive HBsAg serum mothers was 22% and this number decreased with 
the increasing of ages [17]. A study conducted by Tran and his colleagues showed that positive HBeAg serum 
was higher in women at reproductive age; 57.2% at age <44 years and 27.5%at age ≥ 45 years [18]. A study 
conducted in Ethiopia's Yirgalem Hospital obtained 38.2% positive HBeAg serum [19] dan in Ghana obtained 
40% positive HBeAg serum of positive HBsAg serum mothers [20]. 84.2% perinatal infection occurs in infants 
born from positive HBeAg serum mothers and 8.7% in infants from negative HBeAg serum mothers. 90% of 
perinatal infections develop into chronic hepatitis [9]. Transmission from mother to child is the cause of 
perinatal infection. Hepatitis B virus transmission through the placenta is the least transmission way compared 
to infections that occur during labor and postpartum. The mechanism of HBV transmission in the uterus is still 
controversial. Some suspect transmission through the placenta occurs due to placental leakage, placental barrier 
damage, or through father and mononuclear blood cells in peripheral blood [16]. HBeAg is a replicative form of 
the Hepatitis B virus that can cross the placenta and induce in utero HBV-specific T cells tolerance. A study 
conducted by Shrivastava and his colleagues found that the number of regulatory T lymphocytes increased and 
dysfunctional CD8 T cells in infected infants and this played a role in the occurrence of persistent infections and 
suggested further research on the immunopathogenesis of HBV infections that were acquired in utero [10]. 
FOXP3 is a gene located on chromosome Xp11.23 which acts as a marker of Regulatory T cells and has 
immunomodulating functions [13,15,21]. FOXP3 is also related to cell development in humans. A number of 
previous studies have shown that the FOXP3 gene mutation is associated with autoimmune diseases. FOXP3 
polymorphisms are associated with alopecia areata, habitual abortion, systemic lupus erythematosus, and 
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allergic rhinitis, also with susceptibility to preeclampsia  [15]. FOXP3 expression can be triggered by various 
stimuli such as autoantigen to T cells, interactions with microbial metabolites, Transforming Growth Factor-beta 
(TGF-β) and Interleukin-10 (IL-10). Activation of FOXP3 protein inhibits the interaction of Nuclear Factor of 
Activated T cells (NFAT) and Nuclear Factor-kappa beta (NF-kβ) with genes associated with cytokines such as 
Interleukin-4 (IL-4) and Interferon-gamma (IFN-γ) [22]. From table 2, there was no significant difference 
between placental FOXP3 expression with HBeAg serum mothers (p = 0.575 (p > 0.05)). Positive expression of 
FOXP3 in the placenta with negative HBeAg serum was 15 samples and with positive HBeAg serum was 6 
samples. Although there was no statistically significant difference, FOXP3  of Tregs were more expressed in the 
placenta with negative HBeAg serum. This is because the normal pregnancy process also affects the expression 
of Tregs in the placenta.  
Regulatory T lymphocytes have a central role in fetomaternal tolerance and their frequency is increasing in the 
fetomaternal interface. During pregnancy, the immunity of pregnant women decreases to maintain fetal 
development. Estrogen and progesterone hormones are influential in regulating the immune response. 
Progesterone is immunosuppressive by inducing type 2 helper T cells (Th2) to maintain pregnancy. Increased of 
Th2 cells increase the CD4 + CD25 + Tregs [23]. Hu and his colleagues study found that FOXP3 expressed in 
trophoblast cells and decidua of the first-trimester placenta. At the end of the trimester placenta, the expression 
is lower because at the end of pregnancy immunologic changes occur which are characterized by a pro-
inflammatory state for the delivery process. So the decrease of FOXP3 expression causes a shift in immunologic 
status from an immunotolerant state to a pro-inflammatory state at the end of pregnancy [21]. In this study, 
FOXP3 was positively expressed only in lymphocyte cells and not expressed in the trophoblast and decidua 
cells. Low immunity of pregnant women can cause replication of the hepatitis B virus and increase the chance of 
HBV transmission to the baby [21].  
Increased regulatory T cells because the physiological process of pregnancy can create a gap that is prone to 
prenatal infection [24]. In table 3, we correlated FOXP3 expression with intrauterine hepatitis B virus 
transmission and it was found that FOXP3 did not affect the intrauterine transmission of the hepatitis B virus, 
this is probably because of too few samples or because transmission of the hepatitis B virus in our sample did 
not occur through the placenta. There was also no difference in expression of FOXP3 regulatory T lymphocytes 
with HBeAg serum as mentioned before. So that there is a possibility of transplacental HBV infection 
transmission occurs through other immunosuppressive mechanisms or HBeAg does not affect placental 
immunosuppressive conditions because HBeAg particles are so small that they can cross the placental barrier 
and directly into the fetal blood circulation.  The limitation of this study is the number of samples that are too 
small, so it is necessary to conduct research with a larger sample size. 
5. Conclusion 
In this study, we concluded that there was no significant difference between FOXP3 expression in placental with 
both maternal HBeAg serum and intrauterine transmission status, so that maternal HBeAg serum status did not 
affect the expression of FOXP3 in placenta as Regulatory T cells marker, and also FOXP3 did not play a role in 
intrauterine transmission of hepatitis B. 
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